These novel therapies , Retatrutide, represent a remarkable advancement in addressing metabolic dysfunction and possibly other ailments . They all are classified as GLP-1 receptor activators , https://liviaults772449.link4blogs.com/62235270/semaglutide-a-deep-dive-into-incretin-agents